Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The baby is gone.
Like this one:
http://smartsongs.org/stock-market-song
Talking about shorts!
The Moderator's list is getting shorter!
FN
I wonder if Icahn know about NNVC!
He would be an other great investor.
http://topics.bloomberg.com/carl-icahn/
Icahn is a diversified investor with extensive holdings in biotech, casinos, information technology and real estate. About half his fortune is invested in publicly traded companies, including natural gas outfit El Paso and auto parts maker Federal Mogul. His closely held assets include a telecommunications company (XO Holdings) and rail cars (ACF).
Ha Ha!
I am at work and couldn't finish my sentence an accidentally went through !
It's interesting how new investors in NNVC knows already so much about the company.
FN
NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates
NanoViricides, Inc.
3 hours ago
WEST HAVEN, Conn.--(BUSINESS WIRE)--
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"), has filed its quarterly report with the Securities and Exchange Commission on Friday, February 14th, in a timely fashion. The submission can be downloaded from the SEC website at http://www.sec.gov/Archives/edgar/data/1379006/000114420414009813/v367879_10q.htm.
The Company estimates that it now has approximately $38M of current assets plus restricted cash in hand, with the subsequent January 21, 2014 raise, as of the date of filing. The Company estimates that this funding is sufficient to enable us to perform initial human clinical trials of our injectable FluCide™ drug candidate, as well as possibly to advance our DengueCide™ orphan drug candidate towards initial human clinical trials The Company’s estimates are based on its current rate of expenditure and also on certain approximate estimates for clinical development of its drug candidate as gleaned from discussions with various contract research organizations.
The Company reported that it had approximately $19.8M in current assets plus restricted cash (cash, cash equivalents, collateral advance, prepaid expenses, and security deposits) as of December 31, 2013, the end of the reporting quarter. The shareholder equity stood at approximately $10.2M. In comparison, the Company had approximately $22.0M in current assets plus restricted cash, and approximately $11.75M in shareholder equity as of September 30, 2013, the end of previous quarter.
The Company spent approximately $1.13M in Research and Development expenses (R&D) and approximately $621K in General and Administrative expenses (G&A), including stock-based expenses, in the reported quarter. The current rate of expenditure was in line with the Company’s budgeted targets.
On September 25, 2013, the Company’s (new) common stock began trading on NYSE MKT exchange under the symbol “NNVC”. The Company had met or exceeded all of the exchange listing requirements including Corporate Governance, after having established an independent board of directors comprising three independent marquee directors in addition to the two executive ex-officio directors.
The Company reports that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate.
Subsequent to the reporting period, on January 21, 2014, the Company has raised approximately $20M in a registered direct offering. This offering grossed approximately $20M before estimated expenses of approximately $1.2M, which includes placement agent fees but does not include and attorneys’ fees and other expenses. The price per unit was $5.25, with 1 unit comprising 1 share of registered common stock and a 5-year warrant to purchase 0.65 shares at a price of $6.05. Chardan Capital Markets, LLC, acted as lead placement agent and Midtown Partners & Co., LLC was the co-placement agent in connection with the offering.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
Contact:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
Impressive!
You are trying to convince the shareholders to sell for your bank account, but you are using the news that everyone knows already.
you have nothing more concrete?
Yo have no idea who is the guy who wrote that article.
Yes : Check: NV3N.BE
There are 4 countries in Europe who are trading NNVC.
NV3N.BE is German.
I have News for you: NNVC will not go Bankrupt !
FN
Why and to who are you saying that?
Ok now I understand the signification of forward !
Thanks
Where are you from Karin?
Ok! so split and reverse split are the same?
Sh ....t
Sense
And that what I meant!
Revers for me is changing the current price up or down.
so I meant Reversing the price lower from the current price.
As I said to another_voice
I am learning a new word every day.
Today I learned "SPLIT"
I meant a split.
No, he is right !!
Lol
Yes I agree he doesn't make any sence! LOL
Got it ! That what I wanted to said! But you know I learn a new word every days.
I ment the same thing that you are saying: A split.
Yes I know that!
What did I said that you
Think I didn't understand ?
Time will tell!
I think that if they do an other one
They will wait for the stock to be much higher than $100.
If successful with all of their drugs
The stock could approach $1000
it would make sense to reverse the price!
But with flu cide only I wood imagine over $100
The flu is a multi billions Dollars
Market.
Please anyone correct me if I am wrong!
FN
With all the viruses that they have
More than $500
It could be possible that they will do an other reverse split after the 100 marks !
Will see!
FN
The Nano Family !!!!!
I like to be called:
THE ITALIAN STALONE FORZANANO !!!
FORZA NANOOOOOOOOOOOOO!!!!!!
Rocky?
Thanks for the great info you have gave us all this time!
I cannot wait to share a drink with you!!
FN
The marcket is not fooled.
Thank you for posting that info!
Seeking Alpha has not removed the article at the request of NNVC.
Interesting!
After the attack from Pump Terminator,
I registered on seeking alpha's website.
And I wanted to post : "Stock Manipulation In A Bear Market" Post # 80259
They didn't let me posting it.
Yes, this article is very provocative.
I'm even surprised they've published it without thinking whether it was true or false.
As a result, this website has done a lot damage, without doing their own investigation.
Results and consequences, NNVC is suing them.
This website has now a bad reputaton and will have to pay because of their negligence.
Not very smart on their part.
FN
The market is already reacting on that last PR! 11% on the 1 st hour with 600,130 Volume!
Thanks to the pump exterminator, that all mess will come back to our adventage.
More exposure, more buy.
Weedie,
We are supporting a company who is going to be the top N1 company in the world !
We are getting stronger and closer!
We will pass the FDA!
We will sell Nano sides all around the world!
Nothing will stop a great science and a wonderful friendship!
To our success and to you all!
FN